Intensity Therapeutics (NASDAQ: INTS)
$0.25
(-7.6%)
-$0.02
Price as of August 7, 2025, 4:00 p.m. ET
Intensity Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Intensity Therapeutics Company Info
Intensity Therapeutics, Inc. engages in the operation a biotechnology company which develops novel immune-based therapeutic products for cancer treatment. Its product INT230-6, is a formulation consisting of an amphiphilic cell penetration enhancer molecule combined with cisplatin and vinblastine. The company was founded by Lewis H. Bender in 2012 and is headquartered in Westport, CT.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.